{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:19:03Z","timestamp":1785777543423,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CSF"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.beha.2019.02.012","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T07:44:15Z","timestamp":1551167055000},"page":"40-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Myeloid malignancies after treatment for solid tumours"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-2611","authenticated-orcid":false,"given":"Guru Subramanian","family":"Guru Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2019.02.012_bib1","series-title":"Cancer treatment & survivorship facts & figures 2016-2017","year":"2016"},{"key":"10.1016\/j.beha.2019.02.012_bib2","series-title":"Acute leukaemias of ambiguous lineage","author":"Brunning","year":"2001"},{"key":"10.1016\/j.beha.2019.02.012_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloidneoplasms and acute leukaemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.012_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.leukres.2017.01.003","article-title":"Incidences and outcomes of therapy-related chronic myeloid leukaemia in the era of tyrosine kinase inhibitors: surveillance of the CML Cooperative Study Group","volume":"54","year":"2017","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.beha.2019.02.012_bib6","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2004.99.301","article-title":"Prognosis in therapy-related acute myeloid leukaemia and impact of karyotype","volume":"22","author":"Kern","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2019.02.012_bib7","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukaemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.012_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2018.07.013","article-title":"Incidence and survival of therapy related myeloid neoplasm in United States","volume":"71","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.beha.2019.02.012_bib9","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/imj.13714","article-title":"Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014","volume":"48","author":"Ong","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.beha.2019.02.012_bib10","first-page":"51","article-title":"Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010","volume":"3","author":"O'Keefe","year":"2015","journal-title":"Front Public Health"},{"issue":"9","key":"10.1016\/j.beha.2019.02.012_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"10.1016\/j.beha.2019.02.012_bib12","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1001\/jama.1984.03340410063036","article-title":"Nitrogen mustard therapy: use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"251","author":"Goodman","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2019.02.012_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.1986.4.3.325","article-title":"Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7","volume":"4","author":"Le Beau","year":"1986","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.012_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.012_bib15","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1073\/pnas.90.12.5484","article-title":"Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases","volume":"90","author":"LeBeau","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beha.2019.02.012_bib16","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1073\/pnas.95.7.3781","article-title":"Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci","volume":"95","author":"Liang","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.beha.2019.02.012_bib17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mpo.1126","article-title":"Therapy-related leukemia associated with alkylating agents","volume":"36","author":"Davies","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.beha.2019.02.012_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/nyas.12358","article-title":"Topoisomerase II and leukemia","volume":"1310","author":"Pendleton","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.beha.2019.02.012_bib19","first-page":"483","article-title":"Chromosomal abnormalities in secondary MDS and AML: relationship to drugs and radiation with specific emphasis on the balanced rearrangements","volume":"83","author":"Andersen","year":"1998","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2019.02.012_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3904\/kjim.2012.27.1.115","article-title":"A case of therapy-related acute myeloid leukemia following 5-fluorouracil chemotherapy","volume":"27","author":"Park","year":"2012","journal-title":"Korean J Intern Med"},{"issue":"3","key":"10.1016\/j.beha.2019.02.012_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1634\/theoncologist.11-3-261","article-title":"Oxaliplatin-related acute myelogenous leukemia","volume":"11","author":"Carneiro","year":"2006","journal-title":"Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.012_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1600-0609.2007.00864.x","article-title":"Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer","volume":"78","author":"Shapiro","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2019.02.012_bib23","first-page":"8308179","article-title":"Paclitaxel induced MDS and AML: a case report and literature review","volume":"2016","author":"Bhatnagar","year":"2016","journal-title":"Case Rep Oncol Med"},{"issue":"2","key":"10.1016\/j.beha.2019.02.012_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2018.10.013","article-title":"The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: understanding the baseline incidence","volume":"151","author":"Sella","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.012_bib25","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1016\/j.clgc.2017.07.005","article-title":"Acute myeloid leukemia after olaparib treatment in metastatic castration-resistant prostate cancer","volume":"15","author":"Zhu","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.beha.2019.02.012_bib26","series-title":"Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014","author":"Teepen","year":"2018"},{"issue":"1","key":"10.1016\/j.beha.2019.02.012_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10552-015-0682-5","article-title":"Therapy-related acute myeloid leukaemia following radioactive iodine treatment for thyroid cancer","volume":"27","author":"Oluwasanjo","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"10","key":"10.1016\/j.beha.2019.02.012_bib28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.leukres.2014.08.002","article-title":"Why is there so much therapy-related AML and MDS and so little therapy-related CML?","volume":"38","author":"Gale","year":"2014","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.beha.2019.02.012_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2006.05.9048","article-title":"Antracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer","volume":"25","author":"Le Deley","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2019.02.012_bib30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2003.03.114","article-title":"Acute myeloid leukemia and myelodysplastic syndrome agter doxorubicin-cyclophosphamide adjuvante therapy for operable breast cancer: the national surgical adjuvant breast and bowel project experience","volume":"21","author":"Smith","year":"2003","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2019.02.012_bib31","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","article-title":"Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review","volume":"28","author":"Lyman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.012_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation-2016.1.24","article-title":"Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?","volume":"2016","author":"Heuser","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"7540","key":"10.1016\/j.beha.2019.02.012_bib33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.beha.2019.02.012_bib34","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"7432","key":"10.1016\/j.beha.2019.02.012_bib35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11725","article-title":"Breast and ovarian cancer susceptibility collaboration; wellcome trust case control Consortium.Mosaic PPM1D mutations are associated with predisposition to breastand ovarian cancer","volume":"493","author":"Ruark","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.beha.2019.02.012_bib36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2015.79","article-title":"Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients","volume":"112","author":"Zajkowicz","year":"2015","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2019.02.012_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1083\/jcb.201210031","article-title":"Gain-of-function mutations of PPM1D\/Wip1 impair the p53-dependent G1 checkpoint","volume":"201","author":"Kleiblova","year":"2013","journal-title":"J Cell Biol"},{"issue":"7","key":"10.1016\/j.beha.2019.02.012_bib38","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukaemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2019.02.012_bib39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","article-title":"Germline mutations in the DNAdamage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","volume":"49","author":"Schulz","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.beha.2019.02.012_bib40","series-title":"Cancer facts and figures 2018","author":"American Cancer Society","year":"2018"},{"issue":"26","key":"10.1016\/j.beha.2019.02.012_bib41","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","article-title":"Risk of leukemia after chemotherapy and radiation treatment for breast cancer","volume":"326","author":"Curtis","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2019.02.012_bib42","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.069","article-title":"Incidence of acute myeloid leukemia after breast cancer","volume":"3","author":"Valentini","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.beha.2019.02.012_bib43","article-title":"Association of chemotherapy for solid tumors with development of therapy related myelodysplastic syndrome or acute myeloid leukemia in the modern era","author":"Morton","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.012_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2006-01-023101","article-title":"Therapy-related myelodysplasia and acute myeloid leukaemia after Ewing sarcoma and primitive neuroectodermal tumour of bone: a report from the Children's Oncology Group","volume":"109","author":"Bhatia","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.02.012_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199001043220101","article-title":"Leukemia following chemotherapy for ovarian cancer","volume":"322","author":"Kaldor","year":"1990","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2019.02.012_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618301191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618301191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T15:46:47Z","timestamp":1606578407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618301191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1521692618301191"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.012","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid malignancies after treatment for solid tumours","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}